Irbesartan Alter

Irbesartan, the active ingredient in Irbesartan Alter, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It selectively blocks the effects of angiotensin II, helping to lower blood pressure and reduce strain on the heart in adult patients with hypertension, diabetic nephropathy, or heart failure.

GNH USA supplies Irbesartan Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides batch‑tested products with full documentation for regulatory review.

Irbesartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Heart failure: decreases ventricular workload and may improve symptoms in patients with left‑ventricular dysfunction.

Irbesartan may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Dizziness: light‑headedness, especially after the first dose, may resolve with continued therapy. - Headache: mild to moderate head pain that can occur during treatment. - Fatigue: feeling of tiredness or reduced energy levels. - Hyperkalemia: mild elevation of blood potassium levels, often asymptomatic.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or airway requiring emergency care. - Renal impairment: sudden decrease in kidney function, indicated by rising creatinine. - Hepatic injury: signs of liver dysfunction such as jaundice or elevated transaminases.

When prescribing Irbesartan, several precautions should be observed to ensure patient safety.

Blood pressure monitoring: check regularly to ensure therapeutic response and avoid hypotension. Renal function: assess serum creatinine and eGFR before initiation and periodically during treatment. Electrolytes: monitor potassium levels, particularly in patients with renal impairment or on potassium‑sparing diuretics. Pregnancy: contraindicated in pregnancy (Category D); discontinue if pregnancy is confirmed. Drug interactions: review concomitant medications for potential additive hypotensive or hyperkalemic effects. Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight in the original packaging.

Irbesartan can interact with several medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: additive risk of hypotension and renal dysfunction. - Aliskiren (in diabetics): increased risk of renal impairment, hyperkalemia, and hypotension.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive effect and affect renal function. - Spironolactone: can increase potassium levels, requiring monitoring. - Lithium: may increase serum lithium concentrations, necessitating level checks.